COMBAT-COVID
In mechanically ventilated patients with COVID-19 and severe endotheliopathy, does prostacylin compared with placebo, improve days alive without ventilation by day 28?
Continue reading »Special Topic: COVID-19
RECOVERY REGEN-COV
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]
Continue reading »COVID STEROID 2
In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?
Continue reading »COV-BARRIER
In hospitalised adult patient with COVID-19, does baricitinib compared with placebo decrease a composite outcome of progression of illness and mortality?
Continue reading »RECOVERY-RS
In hospitalised patients with COVID-19 requiring >40% FiO2 to achieve SaO2>94%, does the use of continuous positive airway pressure (CPAP) or high flow nasal oxygen (HFNO) compared with conventional O2 therapy (COT) reduce the incidence of tracheal intubation or death within 30 days?
Continue reading »BACC
In hospitalised patients with severe acute respiratory syndrome due to coronavirus 2 (SAR-CoV-2), does tocilizumab compared with placebo, reduce intubation rates or mortality?
Continue reading »REMAP-CAP
In patients with severe COVID-19, does intravenous hydrocortisone (either as a fixed dose or restricted to when shock is clinically evident) compared with standard care, improve 21-day organ support free days?
Continue reading »RECOVERY: COVID-19 dexamethasone
In hospitalised patients with SARS-CoV-2 infection does dexamethasone in additional to usual care, compared to usual care alone, reduce 28-day mortality?
Continue reading »Boulware
In people who have high-risk or moderate-risk exposure to someone with confirmed COVID-19 infection, does taking hydroxychloroquine following the exposure compared to placebo reduce the incidence of a new illness compatible with COVID-19?
Continue reading »